Education
About Us
Working with TipRanks
Follow Us
Mineralys Therapeutics, Inc. (MLYS)
:MLYS
MLYS Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MLYS Stock 12 Month Forecast
Average Price Target
$34.50
▲(135.33% Upside)
| Highest Price Target$45.00 | Average Price Target$34.50 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Stifel Nicolaus
Reiterated
03/31/25
LifeSci Capital
Reiterated
03/30/25
Bank of America Securities
Reiterated
03/13/25
H.C. Wainwright
Reiterated
03/10/25
Goldman Sachs
Reiterated
03/07/25
Guggenheim
Reiterated
02/24/25
Wells Fargo
Reiterated
02/12/25
Citi
$36
Buy
145.57%
Upside
Reiterated
05/13/24
Bank of America Securities Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Stifel Nicolaus
Reiterated
03/31/25
LifeSci Capital
Reiterated
03/30/25
Bank of America Securities
Reiterated
03/13/25
H.C. Wainwright
Reiterated
03/10/25
Goldman Sachs
Reiterated
03/07/25
Guggenheim
Reiterated
02/24/25
Wells Fargo
Reiterated
02/12/25
Citi
$36
Buy
145.57%
Upside
Reiterated
05/13/24
Bank of America Securities Reaffirms Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
MLYS Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Jan 25
Feb 25
Mar 25
Strong Buy
8
7
8
13
17
Buy
1
1
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
8
8
14
18
Each month's total comprises the sum of three months' worth of ratings.
MLYS Financial Forecast
MLYS Stock Forecast FAQ
What is MLYS’s average 12-month price target, according to analysts?
Based on analyst ratings, Mineralys Therapeutics, Inc.’s 12-month average price target is $34.50.
What is MLYS’s upside potential, based on the analysts’ average price target?
Mineralys Therapeutics, Inc. has 135.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MLYS a Buy, Sell or Hold?
Mineralys Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Mineralys Therapeutics, Inc.’s price target?
The average price target for Mineralys Therapeutics, Inc. is $34.50. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.00 ,the lowest forecast is $24.00. The average price target represents 135.33% Increase from the current price of $14.66.
The highest analyst price target is $45.00 ,the lowest forecast is $24.00. The average price target represents 135.33% Increase from the current price of $14.66.
What do analysts say about Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of MLYS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.